INS and COVID-19: While it remains important to continue current regimens for glucose control in patients with mild, self-limiting COVID-19, it appears that insulin may be a good choice for patients with severe COVID-19, while DPP4 inhibitors may also prove to be a good choice, along with insulin, for patients with mild to moderate disease, pending the results of clinical trials currently underway.